Search

Search Constraints

You searched for: Author/Creator Zarour, Hassane

Search Results

1. 303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results. (10th December 2020)

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

4. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

5. 435 A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma. (9th November 2020)

6. Future perspectives in melanoma research. Issue 1 (December 2016)

7. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd–6th 2014. Issue 1 (December 2015)

8. Melanoma and immunotherapy bridge 2015. Issue 1 (July 2016)

9. Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC). (6th November 2014)

10. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28–29 November, 2018, Naples, Italy). Issue 1 (29th November 2019)